HOOKIPA Pharma Inc
NASDAQ:HOOK

Watchlist Manager
HOOKIPA Pharma Inc Logo
HOOKIPA Pharma Inc
NASDAQ:HOOK
Watchlist
Price: 0.87 USD -1.36% Market Closed
Market Cap: 10.7m USD

HOOKIPA Pharma Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

HOOKIPA Pharma Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
HOOKIPA Pharma Inc
NASDAQ:HOOK
Research & Development
-$61.2m
CAGR 3-Years
8%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

HOOKIPA Pharma Inc
Glance View

Market Cap
10.5m USD
Industry
Biotechnology

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.

HOOK Intrinsic Value
2.61 USD
Undervaluation 67%
Intrinsic Value
Price

See Also

What is HOOKIPA Pharma Inc's Research & Development?
Research & Development
-61.2m USD

Based on the financial report for Mar 31, 2025, HOOKIPA Pharma Inc's Research & Development amounts to -61.2m USD.

What is HOOKIPA Pharma Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-6%

Over the last year, the Research & Development growth was 29%. The average annual Research & Development growth rates for HOOKIPA Pharma Inc have been 8% over the past three years , -6% over the past five years .

Back to Top